Browsing Tag
Sofinnova
2 posts
Why Seaport’s U.S. IPO filing matters now for neuropsychiatric drug development and biotech capital markets
Seaport Therapeutics has filed for a U.S. IPO. Read how its neuropsychiatry pipeline could test biotech investor appetite in 2026.
Reynold Lemkins Group expands cross-border biotech investments with VISEN Pharmaceuticals (HKEX: 02561) IPO
Reynold Lemkins Group expands cross-border biotech strategy with VISEN Pharmaceuticals (HKEX: 02561) IPO, aligning capital with Asia’s AI-driven healthcare future.